A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients

This study has been completed.
Sponsor:
Information provided by:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00240448
First received: October 14, 2005
Last updated: November 4, 2013
Last verified: November 2013
  Purpose

The primary objective of this study is to compare the effectiveness of telmisartan 80 mg/hydrochlorothiazide 25 mg [Micardis HCT] to valsartan 160 mg/hydrochlorothiazide 25 mg [Diovan HCT] and placebo in the treatment of Stage 1 and Stage 2 hypertension.


Condition Intervention Phase
Hypertension
Drug: telmisartan 80 mg/hydrochlorothiazide 25 mg
Drug: valsartan 160 mg/hydrochlorothiazide 25 mg
Drug: placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Double-dummy, Placebo-controlled, Forced-titration, Comparison of MICARDIS® HCT (Telmisartan 80 mg / Hydrochlorothiazide 25 mg) Versus DIOVAN® HCT (Valsartan 160 mg / Hydrochlorothiazide 25 mg) Using Seated Trough Cuff Blood Pressure in Patients With Stage 1 and Stage 2 Hypertension

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Change from baseline in mean seated trough cuff diastolic and systolic blood pressure measurements at the end of an 8-week treatment period

Secondary Outcome Measures:
  • Percentage of responders based on change from baseline in cuff diastolic and systolic blood pressure measurements at the end of an 8-week treatment period

Enrollment: 1109
Study Start Date: September 2003
Primary Completion Date: June 2004 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria

  1. Ability to provide written informed consent.
  2. Age 18 years or older.
  3. Ability to stop current antihypertensive therapy without unacceptable risk to the patient (investigator's discretion).
  4. Seated cuff DBP of 95 mmHg at Visit 2 (baseline).

Exclusion criteria

  1. Pre-menopausal women (last menstruation 1 year prior to start of run-in period) who:

    • Are not surgically sterile and/or
    • Are nursing or pregnant
    • Are of child-bearing potential and are NOT practicing acceptable means of birth control, do NOT plan to continue using this method throughout the study and do NOT agree to submit to periodic pregnancy testing during participation in studies of > 3-months duration. Acceptable methods of birth control include oral, implantable, transdermal, or injectable contraceptives, and Intra-Uterine Device (IUD).
  2. Known or suspected secondary hypertension.
  3. Mean seated SBP >= 180 mmHg or mean seated DBP >= 120 mmHg during any clinic visit prior to randomization.
  4. Hepatic and/or renal dysfunction as defined by the following laboratory parameters:

    • SGPT (ALT) or SGOT (AST) > 2 times the upper limit of normal range, or
    • Serum creatinine > 3.0 mg/dL or creatinine clearance < 0.6 ml/sec.
  5. Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant or with only one kidney.
  6. Clinically relevant hypokalemia or hyperkalemia.
  7. Uncorrected volume depletion.
  8. Uncorrected sodium depletion.
  9. Primary aldosteronism.
  10. Hereditary fructose intolerance.
  11. Biliary obstructive disorders, cholestasis or moderate to severe hepatic insufficiency.
  12. Patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists.
  13. History of drug or alcohol dependency within six months prior to start of run-in period.
  14. Chronic administration of any medications known to affect blood pressure, etc.
  15. Any investigational drug therapy within one month of start of run-in period.
  16. known hypersensitivity to any component of the formulation study drugs (telmisartan, valsartan, HCT).
  17. Contra-indication to a placebo run-in period (e.g. stroke within the past six months, MI, cardia surgery, PTCA or angina within the past three months prior to the start of run-in period.
  18. Any other clinical condition which, in the opinion of the principal investigator, would not allow safe completion of the protocol and safe administration of telmisartan, valsartan, or HCT.
  19. Night shift workers.
  20. Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator.
  21. NYHA functional class CHF III-IV.
  22. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve.
  23. Patients whose diabetes has been unstable and uncontrolled for at least the past 3 months as defined by a HbA1c >/= 10%.
  24. Concomitant use of lithium or cholestyramine or colestipol resins (potential drug interactions with HCT).
  25. History of non-compliance with prescribed medication or protocol procedures.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00240448

  Hide Study Locations
Locations
United States, Alabama
Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
Boehringer Ingelheim Investigational Site
Huntsville, Alabama, United States
Boehringer Ingelheim Investigational Site
Mobile, Alabama, United States
United States, Arizona
Boehringer Ingelheim Investigational Site
Sctoosdale, Arizona, United States
Boehringer Ingelheim Investigational Site
Tucson, Arizona, United States
United States, Arkansas
Boehringer Ingelheim Investigational Site
Bentonville, Arkansas, United States
Boehringer Ingelheim Investigational Site
Carlisle, Arkansas, United States
Boehringer Ingelheim Investigational Site
Hot Springs, Arkansas, United States
United States, California
Boehringer Ingelheim Investigational Site
Concord, California, United States
Memorial Research Medical Clinic
Long Beach, California, United States
Boehringer Ingelheim Investigational Site
Orange, California, United States
Boehringer Ingelheim Investigational Site
Riverside, California, United States
Clinical Trials Research
Roseville, California, United States
Boehringer Ingelheim Investigational Site
Sacramento, California, United States
Boehringer Ingelheim Investigational Site
San Leandro, California, United States
Boehringer Ingelheim Investigational Site
Santa Ana, California, United States
Boehringer Ingelheim Investigational Site
Sepulveda, California, United States
Boehringer Ingelheim Investigational Site
Spring Valley, California, United States
Boehringer Ingelheim Investigational Site
Torrance, California, United States
United States, Colorado
Boehringer Ingelheim Investigational Site
Boulder, Colorado, United States
United States, Connecticut
Boehringer Ingelheim Investigational Site
Bridgeport, Connecticut, United States
Boehringer Ingelheim Investigational Site
Farmington, Connecticut, United States
Clinical Research Consultants, Inc.
Trumbull, Connecticut, United States
Boehringer Ingelheim Investigational Site
Waterbury, Connecticut, United States
United States, Delaware
Boehringer Ingelheim Investigational Site
Newark, Delaware, United States
United States, Florida
Boehringer Ingelheim Investigational Site
Coral Gables, Florida, United States
Boehringer Ingelheim Investigational Site
Ft. Lauderdale, Florida, United States
Boehringer Ingelheim Investigational Site
Ft. Myers, Florida, United States
Boehringer Ingelheim Investigational Site
Holiday, Florida, United States
Boehringer Ingelheim Investigational Site
Hollywood, Florida, United States
Christopher Chappel, MD
Kissimmee, Florida, United States
Boehringer Ingelheim Investigational Site
Largo, Florida, United States
Orlando Clinical Research Center
Orlando, Florida, United States
Boehringer Ingelheim Investigational Site
Palm Harbor, Florida, United States
Boehringer Ingelheim Investigational Site
Panama City, Florida, United States
Attention: Larry I. Gilderman, D.O.
Pembroke Pines, Florida, United States
Boehringer Ingelheim Investigational Site
Pembroke Pines, Florida, United States
United States, Georgia
Boehringer Ingelheim Investigational Site
Atlanta, Georgia, United States
Grady Memorial Hospital
Atlanta, Georgia, United States
Boehringer Ingelheim Investigational Site
Conyers, Georgia, United States
United States, Idaho
Treasure Valley Cardiology
Boise, Idaho, United States
United States, Illinois
Boehringer Ingelheim Investigational Site
Chicago, Illinois, United States
Herron Medical Center, Ltd.
Chicago, Illinois, United States
Cedar-Crosse Research Center
Chicago, Illinois, United States
Boehringer Ingelheim Investigational Site
Orland Park, Illinois, United States
N Touch Research
Peoria, Illinois, United States
United States, Indiana
Midwest Institute for Clinical Research Inc.
Indianapolis, Indiana, United States
United States, Iowa
Boehringer Ingelheim Investigational Site
Waterloo, Iowa, United States
United States, Kansas
Boehringer Ingelheim Investigational Site
Shawnee, Kansas, United States
Boehringer Ingelheim Investigational Site
Wichita, Kansas, United States
United States, Kentucky
Boehringer Ingelheim Investigational Site
Louisville, Kentucky, United States
United States, Louisiana
Attn:William Smith
New Orleans, Louisiana, United States
United States, Maryland
Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
United States, Massachusetts
Boehringer Ingelheim Investigational Site
Brookline, Massachusetts, United States
Waltham Hospital
Waltham, Massachusetts, United States
United States, Michigan
Boehringer Ingelheim Investigational Site
Troy, Michigan, United States
United States, Minnesota
Boehringer Ingelheim Investigational Site
Brooklyn Center, Minnesota, United States
Radiant Research
Edina, Minnesota, United States
United States, Mississippi
Boehringer Ingelheim Investigational Site
Jackson, Mississippi, United States
United States, Missouri
Boehringer Ingelheim Investigational Site
Kansas City, Missouri, United States
United States, New Jersey
Department of Medicine
Camden, New Jersey, United States
Boehringer Ingelheim Investigational Site
Cherry Hill, New Jersey, United States
United States, New York
Boehringer Ingelheim Investigational Site
Bronx, New York, United States
Boehringer Ingelheim Investigational Site
Kingston, New York, United States
Northport VAMC - Medical Service (111)
Northport, New York, United States
Boehringer Ingelheim Investigational Site
Rochester, New York, United States
Boehringer Ingelheim Investigational Site
Scarsdale, New York, United States
United States, North Carolina
Boehringer Ingelheim Investigational Site
Burlington, North Carolina, United States
Boehringer Ingelheim Investigational Site
Cary, North Carolina, United States
Boehringer Ingelheim Investigational Site
Durham, North Carolina, United States
Boehringer Ingelheim Investigational Site
Raleigh, North Carolina, United States
Boehringer Ingelheim Investigational Site
Stateville, North Carolina, United States
Boehringer Ingelheim Investigational Site
Winston-Salem, North Carolina, United States
United States, Ohio
Boehringer Ingelheim Investigational Site
Cincinnati, Ohio, United States
Radiant Reseach
Cincinnati, Ohio, United States
Boehringer Ingelheim Investigational Site
Columbus, Ohio, United States
Radiant Research
Columbus, Ohio, United States
Ohio State University
Columbus, Ohio, United States
Boehringer Ingelheim Investigational Site
Mansfield, Ohio, United States
Boehringer Ingelheim Investigational Site
Mogadore, Ohio, United States
United States, Oklahoma
Boehringer Ingelheim Investigational Site
Oklahoma City, Oklahoma, United States
Boehringer Ingelheim Investigational Site
Tulsa, Oklahoma, United States
United States, Pennsylvania
Bock Clinical Research
Collegeville, Pennsylvania, United States
Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania, United States
Boehringer Ingelheim Investigational Site
Pottstown, Pennsylvania, United States
United States, Rhode Island
Boehringer Ingelheim Investigational Site
East Providence, Rhode Island, United States
United States, South Carolina
Boehringer Ingelheim Investigational Site
Greer, South Carolina, United States
United States, Tennessee
Boehringer Ingelheim Investigational Site
Nashville, Tennessee, United States
United States, Texas
Boehringer Ingelheim Investigational Site
Austin, Texas, United States
Boehringer Ingelheim Investigational Site
Carrollton, Texas, United States
Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
Boehringer Ingelheim Investigational Site
Houston, Texas, United States
Boehringer Ingelheim Investigational Site
McKinney, Texas, United States
Boehringer Ingelheim Investigational Site
San Antonio, Texas, United States
United States, Utah
Boehringer Ingelheim Investigational Site
Salt Lake City, Utah, United States
United States, Virginia
Clinical Research Center of N. VA
Falls Church, Virginia, United States
United States, Washington
Boehringer Ingelheim Investigational Site
Lacey, Washington, United States
Boehringer Ingelheim Investigational Site
Lakewood, Washington, United States
United States, Wisconsin
Boehringer Ingelheim Investigational Site
Madison, Wisconsin, United States
Boehringer Ingelheim Investigational Site
Milwaukee, Wisconsin, United States
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Study Coordinator Boehringer Ingelheim
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00240448     History of Changes
Other Study ID Numbers: 502.421
Study First Received: October 14, 2005
Last Updated: November 4, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Hydrochlorothiazide
Valsartan
Telmisartan
Telmisartan, hydrochlorothiazide drug combination
Benzoates
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Pharmacologic Actions
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Antifungal Agents
Anti-Infective Agents

ClinicalTrials.gov processed this record on July 29, 2014